News

Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at hscora@ouhsc.edu so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, July 2, 2018

Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 15th Annual Harold

Hamm Diabetes Center Research Symposium.  This event will be held on Friday, November 16, 2018 

at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be

announced later this summer.  Additional details will be posted on http://haroldhamm.org/  Questions? 

Please email Katie-Hoefling@ouhsc.edu.

 

 

On Friday, June 30, 2018, the Centers for Medicare and Medicaid Services (CMS) will

publish on the Open Payments website, 2017 Open Payments program year data along with

newly submitted and updated payment information for years 2013-2016. If you missed the

opportunity to participate in the April 1-May 15, 2018 review and dispute period, physicians and

teaching hospitals have until December 31, 2018 to review the publicly available data and dispute

any inaccuracies. Drug and device companies may also submit data from previous years and

physicians and teaching hospitals will have until the end of the year to dispute this information as

well.  CMS will refresh the Open Payments data at least once after the June 30th data publication

to reflect updated disputes and other data corrections made since the initial publication (likely

January 2019).

Information about the availability of the 2017 data will be posted on AAMC’s Open Payments

website on June 30th or you can access the data directly on the Open Payments website. Also,

be sure to visit CMS Facts About Open Payments Data webpage which will be updated to include

summary information about the June 2017 data.

As mentioned in previous communications, the AAMC is still collecting feedback on how the Open

Payments program and website could be enhanced or modified and will share these suggestions

with CMS. If you or others at your institution would like to provide feedback, you can go to the

following link: https://surveys.aamc.org/se/7C7E87CB104AC3BF. You may also email your comments

directly to Darla Grayer.   

If you have any questions, feel free to contact:  Heather H. Pierce, JD, MPH (hpierce@aamc.org,

202-478-9926), Senior Director, Science Policy, Regulatory Counsel, Scientific Affairs or Daria C.

Grayer, JD, MA (dgrayer@aamc.org, 202-741-5474) Sr. Lead Specialist, Science Policy and

Regulations.

Links:

https://openpaymentsdata.cms.gov/

https://www.aamc.org/initiatives/research/coi/386774/sunshineact.html

https://openpaymentsdata.cms.gov/summary

Irena Tartakovsky, M.D., M.S.

Director, Constituent Engagement

Association of American Medical Colleges

Tel: 202-862-6134

itartakovsky@aamc.org

 

 

The Oklahoma Clinical and Translational Science Institute (OCTSI) is soliciting applications

for opioid-related research pilot grants funded through its Oklahoma Shared Clinical and Translational

Resources (OSCTR) Pilot Grants Program.

Submission Deadline:  Monday, July 9 at 5:00 PM CDT

Purpose: The purpose of this program is to provide funding to develop new and/or expand ongoing

pilot projects to address the opioid epidemic in rural and underserved communities in one or more of

the following areas: treatment for opioid use disorder, prevention, recovery/rehabilitation, and pain

management. The program encourages collaborative and/or multidisciplinary projects between

investigators of the OSCTR member and affiliated member institutions including the University of

Oklahoma Health Sciences Center (Oklahoma City), University of Oklahoma (Norman Campus),

University of Oklahoma (Tulsa campus), Oklahoma Medical Research Foundation, Oklahoma

Physician Resources/Research Network, Southern Plains Tribal Health Board Veteran’s Affairs

Medical Center (Oklahoma City), Oklahoma State University (Stillwater), Oklahoma State University

Center for Health Sciences, Chickasaw Nation, Cherokee Nation, Choctaw Nation, Absentee Shawnee

Tribe, Kiowa Nation, Oklahoma City Indian Clinic, Oklahoma State Health Department, Laureate

Institute for Brain Research, University of Tulsa, Oklahoma Blood Institute, and Dean McGee Eye

Institute.  Find more information at http://osctr.ouhsc.edu/opioidpilots/

 

 

NIH NOTICES

 

Clarification: Assignment Deadlines for Applications Submitted Under the NIH Continuous

Submission Policy (NOT-OD-18-178)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-178.html

 

Notice of Addition of Letter of Intent Due Dates on BRAIN Initiative: Theories, Models and

Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

(NOT-EB-18-022)
https://grants.nih.gov/grants/guide/notice-files/NOT-EB-18-022.html

 

Notice of Availability of Administrative Supplements for NIH Grants that are NOT Focused

on Down Syndrome to Address Specific Down Syndrome Research Objectives (NOT-OD-18-194)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-194.html

 

Notice of Availability of Administrative Supplements for NIH Grants Focused on Down

Syndrome to Address Specific Down Syndrome Research Objectives (NOT-OD-18-195)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-194.html

 

Notice of Change to Eligible Organizations in NIAID PAR-18-335 Global Infectious Disease

Research Administration Development Award for Low-and Middle-Income Country Institutions

(G11 Clinical Trial Not Allowed) (NOT-AI-18-041)
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-18-041.html

 

Notice of Clarification of NIA intent to fund awards for RFA-HL-18-023 "Stimulating Access to

Research in Residency (StARR) (R38)" (NOT-AG-18-022)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-022.html

 

Notice of Clarification for Submission of Materials Related to Communications with the FDA for

RFA-NS-18-011 "Translational Neural Devices (UG3/UH3 Clinical Trial Required)"

(NOT-NS-18-063)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-063.html

 

Notice of Clarification for Submission of Materials Related to Communications with FDA for

RFA-NS-18-012 "Translational Neural Devices (U44 Clinical Trial Required)" (NOT-NS-18-064)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-064.html

 

Notice of Clarification for Submission of Materials Related to Communications with FDA for

RFA-NS-18-021 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and

Modulation in the Human Central Nervous System (UG3/UH3)" (NOT-NS-18-065)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-065.html

 

Notice of Clarification for Submission of Materials Related to Communications with FDA for

RFA-NS-18-022 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and

Modulation in the Human Central Nervous System (U44)" (NOT-NS-18-066)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-066.html

 

Notice of Clarification for Submission of Materials Related to Communications with FDA for

RFA-NS-18-023 "BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive

Devices for Recording and Modulation in the Human Central Nervous System" (NOT-NS-18-067)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-067.html

 

Notice of Correction to NOT-OD-18-174 "Notice of Intent to Publish a Funding Opportunity

Announcement for the Predoctoral Training in Advanced Data Analytics for Behavioral and

Social Sciences Research (BSSR) Institutional Research Training Program [T32]"

(NOT-OD-18-193)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-193.html

 

Notice of NIMH's Interest in Studies of Neural Circuitry Linked to Computationally-Defined

Behaviors of Relevance to Psychiatry in Rodents and Non-Human Primates (NOT-MH-18-036)
https://grants.nih.gov/grants/guide/notice-files/NOT-MH-18-036.html

 

Notice of Pre-Submission Webinars for RFA-TR-18-020: Rare Diseases Clinical Research

Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical

Trial Optional) and RFA-TR-18-021: Data Management and Coordinating Center (DMCC)

(NOT-TR-18-029)
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-18-029.html

 

Notice of U.S. Department of Agriculture (USDA) Participation in PAR-17-482 Comparative

Genomics Research Program (R01) (NOT-HG-18-007)
https://grants.nih.gov/grants/guide/notice-files/NOT-HG-18-007.html

 

Notice Regarding New Applications for PAR-15-303: "Occupational Safety and Health Education

and Research Centers (42)" (NOT-OH-18-008)
https://grants.nih.gov/grants/guide/notice-files/NOT-OH-18-008.html

 

Notice to Extend the Expiration Date for PAR-15-350 "Emerging Directions for Addressing Health

Disparities in Alzheimer's Disease (R03)" (NOT-AG-18-015)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-015.html

 

Notice to Extend the Expiration Date for PAR-15-357 "Understanding Alzheimer's Disease in the

Context of the Aging Brain (R01)" (NOT-AG-18-017)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-017.html

 

Notice to Extend the Expiration Date for PAR-15-359 "Novel Approaches to Diagnosing

Alzheimer's Disease & Predicting Progression (R01)" (NOT-AG-18-019)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-019.html

 

Notice to Extend the Expiration Date for PAR-18-027 "Research on Informal and Formal

Caregiving for Alzheimer's Disease (R01 Clinical Trial Optional)" (NOT-AG-18-020)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-020.html

 

Notice to Extend the Expiration Date for PAR-18-179 "Research on Informal and Formal

Caregiving for Alzheimer's Disease (R21 Clinical Trial Optional)" (NOT-AG-18-021)
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-18-021.html

 

Request for Information (RFI): Evaluation of the NIH Senator Paul D. Wellstone Muscular

Dystrophy Research Centers Program (NOT-AR-18-021)
https://grants.nih.gov/grants/guide/notice-files/NOT-AR-18-021.html

 

Strengthen Regulatory Systems to Ensure the Safety and Quality of Food and Medical

Products (U01) (NOT-FD-18-012
https://grants.nih.gov/grants/guide/notice-files/NOT-FD-18-012.html

 

Strengthening Global Competency and Capacity in Inspectional Approaches and Good

Manufacturing Practices (GMP) (U01) (NOT-FD-18-013)
https://grants.nih.gov/grants/guide/notice-files/NOT-FD-18-013.html

 

 

Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least one month prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.

 

NIH DEADLINES

 

Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp

Clinical Trial Not Allowed) (PA-18-837) – Deadline: Applications are accepted on a rolling basis at

any time starting 30 days after the Open Date until the expiration date, unless otherwise noted in

Institute specific language. Please consult with Scientific contacts listed in Section VII. Applicants

are encouraged to apply early to allow adequate time to make any corrections to errors found in

the application during the submission process by the due date.

https://grants.nih.gov/grants/guide/pa-files/PA-18-837.html

 

Collaborative Human Tissue Network (CHTN) (UM1 Clinical Trials Not Allowed) (RFA-CA-18-025)

Deadline August 28, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-025.html

 

Enhancing Developmental Biology Research at Academic Research Enhancement Award Eligible

Institutions (R15 - Clinical Trial Not Allowed) (PAR-18-834) – Deadline September 18, 2018
https://grants.nih.gov/grants/guide/pa-files/PAR-18-834.html

 

Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials

Optional) (PAR-18-835) – Deadline November 7, 2018
https://grants.nih.gov/grants/guide/pa-files/PAR-18-835.html

 

Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial

Optional) (PAR-18-836) – Deadline November 7, 2018
https://grants.nih.gov/grants/guide/pa-files/PAR-18-836.html

 

High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Not Allowed)

(RFA-AG-19-015) – Deadline February 1, 2019
https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-19-015.html

 

High-Priority Behavioral and Social Research Networks in Alzheimer's Disease and Alzheimer's

Disease Related Dementias (R24 Clinical Trial Not Allowed) (RFA-AG-19-016)

Deadline February 1, 2019
https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-19-016.html

 

Modeling and Simulation to Optimize HIV Prevention Research (MS OPR) (R01 Clinical Trial

not allowed) (RFA-AI-18-026) – Deadline December 13, 2018
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-026.html

 

 

OTHER DEADLINES

European Research Council (ERC) – Advanced Grants – Deadline August 30, 2018

https://erc.europa.eu/funding/advanced-grants

 

ERC - Proof of Concept – Deadline September 11, 2018

https://erc.europa.eu/funding/proof-concept

 

 

NEW CLINICAL STUDY OPPORTUNITIES

***************************************************

Please note this is NOT a solicitation for study subject

***************************************************

Several Pharmaceutical companies are looking for Principal Investigators to participate in the

following clinical studies:

  • Phase 2 Study Is Exploring The Efficacy And Safety Of Various Doses Of Ponatinib For

The Treatment Of Chronic Myeloid Leukemia (CML)

  • Phase III Study Of An Investigational Disease-Modifying, Angiogenic Gene Therapy 

To Treat Patients With Refractory Angina Due To Myocardial Ischemia (00115914)

  • Treating Pediatrics with Secondary Hyperparathyroidism in Chronic Kidney Disease

Undergoing Hemodialysis (Phase 3) 20140315

  • Urothelial cancer with FGFR Mutations  232818
  • Asthma Pediatric 221699

Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more

information on any of these studies. The resulting confidentiality and/or clinical study

agreement will need to be routed to the Office of Research Administration.

 

Print

Name:
Email:
Subject:
Message:
x